---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-109133"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-09T23:59:13.671918+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports RZ358 resolves hypoglycemia in tumor-mediated hyperinsulinism patient

## Summary
- RZ358 administered on compassionate-use basis to patient with refractory hypoglycemia due to metastatic insulin-secreting cervical cancer.
- Treatment started September 2023; resulted in resolution of hypoglycemia and enabled hospital discharge to resume cancer therapy.
- Prior metastatic insulinoma patient has remained on RZ358 for nearly a year; case published in NEJM (389;8).
- Company sees RZ358 as potential universal treatment for hyperinsulinism; evaluating next steps in additional indications.

## SEC filing metadata
- accession: 0001104659-23-109133
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465923109133/0001104659-23-109133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465923109133/tm2328296d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-109133
- JSON: https://secwatch.observer/filing/0001104659-23-109133.json
- Plain text: https://secwatch.observer/filing/0001104659-23-109133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.